Literature DB >> 12736535

Validation study of a CT-based weighted rating scale for subcortical ischemic vascular disease in patients with mild cognitive deterioration.

Cristina Geroldi1, Samantha Galluzzi, Cristina Testa, Orazio Zanetti, Giovanni B Frisoni.   

Abstract

OBJECTIVES: Subcortical ischemic vascular disease (SIVD) is frequently associated with cognitive impairment. Rating scales to grade cerebrovascular disease are available, but their sensitivity to the clinical features of mild SIVD is unclear. The aim of the study is to devise and validate a computed tomography (CT)-based visual rating scale sensitive to SIVD in patients with mild cognitive deterioration.
METHODS: Subjects were 122 consecutive outpatients of a memory clinic (mean age +/- SD 77 +/- 8 years, 71% females, mean +/- SD score of mental state exam 22 +/- 3, 61% with clinical dementia rating of 0.5 and 39% of 1). Diffuse leukoaraiosis, fuzzy and patchy lesions, and lacunes were assessed on ordinary CT films and weights were computed based on clinical indicators of SIVD. A continuous score and an ordinal class (0-3) with higher values indicating higher vascular damage were derived.
RESULTS: Intraclass correlation coefficients for intra- and interrater reliability of the subcortical vascular score and class ranged from 0.84 to 0.88. Convergent validity versus the scale of Wahlund et al. was good (Spearman's correlation coefficient between 0.53 and 0.73, p < 0.0005). Known-group validity was assessed versus clinical diagnoses of degenerative (mild cognitive impairment determined by Petersen et al. and NINCDS-ADRDA probable Alzheimer's disease; n = 58), mixed (possible Alzheimer's disease with cerebrovascular disease; n = 21), and vascular cognitive impairment (criteria of Erkinjuntti et al. for subcortical vascular dementia and cognitive impairment; n = 43). Patients with degenerative cognitive impairment were more often in the lower subcortical vascular classes (43% in class 0, 43% in class 1, 14% in class 2, and 0% in class 3), while patients with mixed (0, 24, 24, and 52%) and vascular cognitive impairment were in increasingly higher subcortical vascular classes (0, 12, 35, 53%; p < 0.00005). Criterion-related validity was assessed versus clinical indicators of cerebrovascular disease. Hypertension, platelet aggregation inhibitor use, balance, gait, and bradykinesia increased linearly with increasing subcortical vascular class (p for trend <0.02).
CONCLUSIONS: This rating scale is valid and sensitive to capture different degrees of SIVD associated with mild cognitive deterioration. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2003        PMID: 12736535     DOI: 10.1159/000070183

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  5 in total

1.  Progression to dementia in a population with amnestic mild cognitive impairment: clinical variables associated with conversion.

Authors:  Marco Mauri; Elena Sinforiani; Chiara Zucchella; Maria Giovanna Cuzzoni; Giorgio Bono
Journal:  Funct Neurol       Date:  2012 Jan-Mar

2.  Extent of white matter lesions is related to acute subcortical infarcts and predicts further stroke risk in patients with first ever ischaemic stroke.

Authors:  J H Fu; C Z Lu; Z Hong; Q Dong; Y Luo; K S Wong
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06       Impact factor: 10.154

3.  Altered callosal function in cerebral microangiopathy.

Authors:  Matthias Wittstock; Annette Grossmann; Erwin Kunesch; Uwe Walter; Reiner Benecke; Alexander Wolters
Journal:  J Neurol       Date:  2009-11-16       Impact factor: 4.849

4.  Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia.

Authors:  Jack C de la Torre
Journal:  Cardiovasc Psychiatry Neurol       Date:  2012-12-03

5.  Progression to vascular dementia of patients with mild cognitive impairment: relevance of mild parkinsonian signs.

Authors:  Marco Mauri; Simona Corbetta; Cristina Pianezzola; Elena Ambrosoni; Giulio Riboldazzi; Giorgio Bono
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.